These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 23289683)
1. Concepts of risk in nanomedicine research. Hogle LF J Law Med Ethics; 2012; 40(4):809-22. PubMed ID: 23289683 [TBL] [Abstract][Full Text] [Related]
2. Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field. Fatehi L; Wolf SM; McCullough J; Hall R; Lawrenz F; Kahn JP; Jones C; Campbell SA; Dresser RS; Erdman AG; Haynes CL; Hoerr RA; Hogle LF; Keane MA; Khushf G; King NM; Kokkoli E; Marchant G; Maynard AD; Philbert M; Ramachandran G; Siegel RA; Wickline S J Law Med Ethics; 2012; 40(4):716-50. PubMed ID: 23289677 [TBL] [Abstract][Full Text] [Related]
3. Building an ethical foundation for first-in-human nanotrials. Dresser R J Law Med Ethics; 2012; 40(4):802-8. PubMed ID: 23289682 [TBL] [Abstract][Full Text] [Related]
4. A portrait of nanomedicine and its bioethical implications. Hall RM; Sun T; Ferrari M J Law Med Ethics; 2012; 40(4):763-79. PubMed ID: 23289679 [TBL] [Abstract][Full Text] [Related]
5. Ethics committees in the United States. Capron AM Not Polit; 2002; 18(67):87-94. PubMed ID: 15282924 [No Abstract] [Full Text] [Related]
6. Introduction: the challenge of nanomedicine human subjects research: protecting participants, workers, bystanders, and the environment. Wolf SM J Law Med Ethics; 2012; 40(4):712-5. PubMed ID: 23289676 [No Abstract] [Full Text] [Related]
7. Ethical oversight of research in developing countries. Kass N; Dawson L; Loyo-Berrios NI IRB; 2003; 25(2):1-10. PubMed ID: 12833901 [No Abstract] [Full Text] [Related]
8. Nanomedicine first-in-human research: challenges for informed consent. King NM J Law Med Ethics; 2012; 40(4):823-30. PubMed ID: 23289684 [TBL] [Abstract][Full Text] [Related]
9. Research involving children: regulations, review boards and reform. Gandhi R J Health Care Law Policy; 2005; 8(2):264-330. PubMed ID: 16471026 [No Abstract] [Full Text] [Related]
10. In focus. The brief career of a government advisory committee: one members's perspective. The life and death of the National Human Research Protections Advisory Committee (NHRPAC). Moreno JD Am J Bioeth; 2002; 2(4):W23. PubMed ID: 12778944 [No Abstract] [Full Text] [Related]
11. Ethics. Human health research ethics. Silbergeld E; Lerman S; Hushka L Science; 2004 Aug; 305(5686):949. PubMed ID: 15310879 [No Abstract] [Full Text] [Related]
13. Beyond human subjects: risk, ethics, and clinical development of nanomedicines. Kimmelman J J Law Med Ethics; 2012; 40(4):841-7. PubMed ID: 23289686 [TBL] [Abstract][Full Text] [Related]
14. The institutional review board and beyond: future challenges to the ethics of human experimentation. Edgar H; Rothman DJ Milbank Q; 1995; 73(4):489-506. PubMed ID: 7491097 [TBL] [Abstract][Full Text] [Related]
15. National commission proposes numerous new regulations of institutional review boards. Maloney DM Hum Res Rep; 1998 Oct; 13(10):1-2. PubMed ID: 11657739 [No Abstract] [Full Text] [Related]
16. Prudent precaution in clinical trials of nanomedicines. Marchant GE; Lindor RA J Law Med Ethics; 2012; 40(4):831-40. PubMed ID: 23289685 [TBL] [Abstract][Full Text] [Related]
17. Responsible conduct in nanomedicine research: environmental concerns beyond the common rule. Resnik DB J Law Med Ethics; 2012; 40(4):848-55. PubMed ID: 23289687 [TBL] [Abstract][Full Text] [Related]
18. Universal protection for all human research participants. Maloney DM Hum Res Rep; 2001 Jul; 16(7):1-2. PubMed ID: 11933953 [No Abstract] [Full Text] [Related]
19. IRBs: protecting the well-being of subject-participants with mental disorders that may affect decisionmaking capacity. Baylis F Account Res; 1999; 7(2-4):183-99. PubMed ID: 11658175 [No Abstract] [Full Text] [Related]